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ABSTRACT
Introduction: Among ex-opioid users on methadone maintenance therapy (MMT), the prevalence of chronic severe pain 
(CSP) was reported as 37-48.2%. The CSP causes distress, adversely affects quality of life, addiction treatment outcome and 
exacerbates patients ambivalence towards MMT. Neuroticism personality trait is associated with CSP, but the similar associa-
tion has yet to be explored in ex-opioid users on MMT.
Objectives: This study aims to determine the prevalence of CSP among ex-opioid users on MMT, and to examine whether 
neuroticism is significantly associated with CSP. 
Methods: In this cross-sectional study, validated Malay version of big five inventory (BFI), brief pain inventory (BPI), Beck's 
depression inventory (BDI), and Beck's anxiety inventory (BAI) were utilized for measurement of neuroticism, pain, depression 
and anxiety symptoms, respectively. Subjects were recruited from two MMT centres in Alor Star, Malaysia.
Results: A total of 151 subjects were recruited, consisting of 104 from Klinik Kesihatan Bandar Alor Setar, and 47 from 
Hospital Sultanah Bahiyah. The prevalence of CSP, regular use of over-the-counter (OTC) analgesics and kratom product were 
22.5%, 28.5%, and 40.4%, respectively. Using multiple logistic regression analyses, neuroticism score (p < 0.001), BAI score (p = 
0.012) and regular OTC analgesic use (p = 0.016) were found to be statistically significant in association with CSP, with adjusted 
odds ratio of 1.60 (95% CI 1.27, 2.12), 1.44 (95% CI 1.08, 1.93), and 3.56 (95% CI 1.27, 10.01), respectively.
Conclusion: Neuroticism, anxiety and regular use of OTC analgesics were independently associated with CSP among ex-opi-
oid users on MMT. Otherwise, no significant association was observed for depression, HIV status, regular use of kratom, and 
other socio-demographic or clinical characteristics.
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INTRODUCTION
The prevalence of chronic severe pain (CSP) among previous heroin 
users on methadone maintenance therapy (MMT) is 37-48.2%1-3) com-
pared to 10% in general population4). Poorly controlled chronic pain is 
associated with disability and distress5), poor addiction outcome1,2), and 
poor quality of life6) among patients on MMT. Counselors also reported 
difficulties in helping patients on MMT with chronic pain7) whereas 
attendance at counseling sessions predict good treatment response8). 
Pain symptoms tend to exacerbate patients anxiety and ambivalence 
towards MMT9).
Neuroticism is one of the personality traits in both the three and five 
factors models of personality, also widely known as the Big Three and 
Big Five theories, respectively10). The differences among various defini-
tions of neuroticism have been reconciled in the late 1990s with the con-
sensus definition that, at its core, neuroticism is the propensity to expe-
rience negative emotions11). Neuroticism is associated with vigilance to 
pain and its severity, and these relationships are mediated by pain cata-
strophizing and pain-related fear12).
Among patients on MMT, significant associations were found 
between CSP and depression as well as anxiety disorders1,3,6,13). Long-
term use of opioids, like methadone, might actually cause opioid-in-
duced hyperalgesia, where patient become more sensitive to pain per-
ception as compared to unexposed individual14-16). Nevertheless, kratom 
has been used as opioid substitute17) and analgesic through its activity on 
opioid receptors17,18) by the local people in Thailand and Malaysia. The 
determinants of chronic severe pain among patients on MMT are likely 
to be complex and warrant further study.
Previous studies had shown that CSP and neuroticism might 
adversely affect MMT, which is an important part of harm reduction 
program in Malaysia19). Therefore, this study aimed to determine the 
prevalence of CSP among patients on MMT in Alor Setar, and its asso-
ciation with neuroticism. It is hoped that the findings of this study 
would help in improving the service of MMT in the future.
METHODS
Study setting and subjects
The ethical approval was sought from the USM Human Research 
Ethics Committee (HREC) and National Medical Research Register of 
Malaysia (NMRR). This cross-sectional study was conducted from July 
to September 2016 at 2 methadone clinics in Alor Setar i.e., Klinik 
Kesihatan Bandar Alor Star (KKBAS) and Hospital Sultanah Bahiyah 
(HSB).
The inclusion criteria were MMT minimum duration of 12 months, 
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stable dose of methadone, chronic pain symptoms of at least 6 months, 
and adequate command of Malay language and literacy to complete the 
self-rated questionnaires. A complete patient information sheet was 
given to eligible subjects for their reading, and the study was explained 
to them verbally, before consent being acquired. Consented subjects 
Table 1. Socio-demographic and clinical characteristics subjects
Characteristics (n = 151) n (%)
Sex
Male 147 (97.4)
Female 4 (2.6)
Race
Malay 138 (91.4)
Chinese 8 (5.3)
Indian 5 (3.3)
Marital Status
Married 75 (49.7)
Single 63 (41.7)
Divorced 3 (2.0)
Widowed 10 (6.6)
Employment Status
Unemployed 28 (18.5)
Employed  123 (81.5)
Educational Status
Primary 10 (6.6)
Secondary 134 (88.7)
Tertiary  7 (4.6)
History of bone fracture > 6 months
Yes 38 (25.2)
No 113 (74.8)
Diagnosis of mental illness
Yes  28 (18.5)
No  123 (81.5)
Chronic medical illness a
Yes 47 (31.1)
No 104 (68.9)
Regular use of over-the-counter analgesics b
Yes 43 (28.5)
No 108 (71.5)
Regular use of kratom c
Yes 61 (40.4)
No 90 (59.6)
Chronic smoker
Yes 135 (89.4)
No 16 (10.6)
Urine toxicology screen for the past month d
Positive 8 (5.3)
Negative 143 (94.7)
Hepatitis C status
Reactive 112 (74.2)
Non-reactive 39 (25.8)
Hepatitis B status
Reactive 15 (9.9)
Non-reactive 136 (90.1)
HIV status
Positive 15 (9.9)
Negative 136 (90.1)
 Mean(SD)
Age (years) 42.08 (8.66)
Duration of MMT (months) 74.00 (37.02)
Current dose of methadone (mg/day) 64.93 (29.61)
Neuroticism score 23.90 (5.77)
BDI score 8.51 (6.82)
BAI score 9.93 (10.50)
a Except hepatitis B, hepatitis C, and HIV 
b Use of over-the-counter analgesics for at least 3 times a week for the past 3 months
c Use of any kratom products daily
d Urine positive for any of the following: morphine, amphetamine, methamphetamine, benzo-
diazepines or tetrahydrocannabinol
Table 2. Factors significantly associated with CSP using simple 
logistic regression
Variable Regression Crude Wald p-
 Co-efficient  Odds Ratio  statistic value
 (b) (95%CI)
Neuroticism  0.313 1.367  26.07 < 0.001
score  (1.212, 1.541)
BAI score 0.056 1.057  10.27 0.001
  (1.022, 1.094)
BDI score 0.125 1.133  17.2 < 0.001
  (1.068, 1.202)
Positive HIV 1.262 3.532  5.07 0.024
  (1.178, 10.595)
Regular use of  0.974 2.648  5.97 0.015
kratom  (1.212, 5.785)
Regular use of  1.253 3.500  9.4 0.002
OTC analgesics  (1.571, 7.799)
* SLR for all other independent variables yield p value > 0.25
Table 3. Factors significantly associated with CSP using multi-
ple logistic regression
Variable Regression Adjusted a Wald p-
 Co-efficient  Odds Ratio  statistic value
 (b) (95%CI)
Neuroticism  0.300 1.349  20.89 < 0.001
score  (1.187, 1.534)
BAI score 0.050 1.051 5.60 0.018
  (1.009, 1.095) 
Regular use of  1.100 3.004  4.75 0.029
OTC analgesics  (1.117, 8.078)
a Forward LR and Backward LR Multiple Logistic Regression model were applied and 
similar
variables were retained in the model. Multicollinearity was checked and not found.
Interaction term was checked and it showed interaction between neuroticism score and 
BAI score (p = 0.028, b = -0.012).
Table 4. Factors significantly associated with CSP using multi-
ple logistic regression with interaction term included 
(final model)
Variable Regression Adjusted a Wald p-
 Co-efficient  Odds Ratio  statistic value
 (b) (95%CI)
Neuroticism  0.472 1.603  16.24 < 0.001
score  (1.274, 2.016)
BAI score 0.368 1.444  6.24 0.012
  (1.082, 1.927)
Regular use of  1.269 3.558  5.78 0.016
OTC analgesics  (1.265, 10.011)
BAI score* -0.012 0.988  4.81 0.028
Neuroticism   (0.978, 0.999)
score b
a Interaction term was checked and it showed interaction between neuroticism score and 
BAI score (p = 0.028, b= -0.012). 
b Interaction term created for interaction between neuroticism score and BAI score is 
included into the final model.
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were requested to complete a series of questionnaires, including a data 
sheet on socio-demographic and clinical characteristics. Patients who 
declined the invitation to participate were being assured that the standard 
of their MMT in the future will not be affected. This was explicitly stated 
in patient information sheet to address the issue of subjects' vulnerability.
Measurements
The brief pain inventory (BPI) is a widely used instrument in clini-
cal pain assessment. It has been used in hundreds of studies and has 
been shown to be an appropriated measure for pain due to a wide range 
of clinical conditions. BPI was initially used to measure the pain in 
malignancy, but it has been validated for use in chronic non-malignant 
pain as well20). Malay version of BPI was validated and used in this 
study21). A subject is said to have CSP if he or she scores 5 or higher on 
the BPI 'worst pain' scale in the past one week, or obtain the mean 'pain 
interference' score of 5 or above, given that at least four out of the seven 
interference scales are scored. Furthermore, the pattern of pain should 
present for at least 6 months1,3).
The big five inventory (BFI) is a valid and reliable instrument to 
measure personality traits according to big five theory or five-factor 
model of personality22,23). It is an efficient measuring instrument whereby 
it only takes about 5 minutes to be completed, as compared to NEO- FFI 
that usually take 15 minutes to complete. It was shown to be at least as 
efficient and easily understood as the 60 item NEO-FFI. It has good 
internal consistency, as well as convergent validity with NEO-FFI23). 
The translated Malay version of BFI had been validated for use in 
Malaysian population24). The inventory consists of 44 items that measure 
big five attributes, i.e., neuroticism (8 items), extraversion (8 items), 
agreeableness (9 items), conscientiousness (9 items), and openness (10 
items). Only the neuroticism items were used in this study.
The Beck's depression inventory (BDI) is a well-established self-re-
ported instrument25), and has been used worldwide for the past 5 decades 
to measure depressive symptoms. It had since been translated into vari-
ous languages26), including Malay language27), and its psychometric 
properties have been extensively evaluated. The Beck's anxiety invento-
ry (BAI) is widely used for measurement of anxiety symptoms. It has 
good internal consistency and high test-retest reliability. The Malay ver-
sion of BAI was validated by local researchers28) and used in this study.
Statistical analyses
The data were analysed by using SPSS Statistic version 22. The 
association between potential associative factors and the presence of 
CSP were first analysed using simple logistic regression (SLR). The 
associative factors with p-value < 0.25 by SLR were then further anal-
ysed using multiple logistic regression (MLR). During the variable 
selection processes, forward selection was coupled with backward elim-
ination in order to acquire preliminary main effect model. Alpha was set 
at 0.05. Multicollinearity and interaction were checked, and the fitness 
of the preliminary final model was assessed using Hosmer-Lemeshow 
test, classification table, and area under the receiver operating character-
istic (ROC) curve tests. 
RESULTS
A total of 34 subjects (22.5%) reported chronic severe pain. The 
socio-demographic and clinical characteristics of study subjects (n = 151) 
were summarized in table 1. The mean age of subjects was 42 (SD 8.66). 
Over 90% of the subjects were Malay and only 4 (2.6%) female subjects 
were recruited in the study. The employment rate was 81.5%. The mean 
daily dose of methadone was 64.9mg (SD 29.6), ranging 5.0 to 190.0mg 
daily. Thirty-eight (25.2%) subjects had a history of bone fracture within 
6 months of study, and all of them reported full recovery from the inju-
ries. Twenty-eight (18.5%) subjects had a diagnosis of any mental illness, 
whereas 31% reported having at least one chronic medical illness, such 
as diabetes mellitus, hypertension, bronchial asthma, and cardiovascular 
disorders. The rate of hepatitis C infection was 74.2%, while hepatitis B 
and HIV infection were reported to be similar (15%). Regular over-the-
counter (OTC) analgesics usage was common (28.5%), and it was inter-
esting to note that the prevalence of regular use of kratom product was 
40.4%. Though no subject reports active use of any illicit substance, 
5.3% were positive in urine toxicology screening done within 1 month 
from sampling date. The rate of active smoking was 89.4%.
Table 2 summarizes all factors that found to be associated with the 
presence of CSP using SLR analyses. Neuroticism (p < 0.001), BAI (p = 
0.001) and BDI (p < 0.001) scores were noted to be positively associat-
ed with CSP. Besides, HIV infection (p = 0.024), regular use of kratom 
(p = 0.015) and OTC analgesics (p = 0.002) were also significantly 
associated with CSP, all with crude OR of over 2.50.
Table 3 listed the three factors from above that remained statistical-
ly significant after MLR analyses were performed, i.e. neuroticism score 
(p < 0.001), BAI score (p = 0.018) and regular use of OTC analgesics (p 
= 0.029), with adjusted OR of 1.35 (95% CI 1.19, 1.53), 1.05 (95% CI 
1.01, 1.10) and 3.00 (95% CI 1.12, 8.08), respectively. Although no 
multicollinearity detected, a significant interaction was found between 
neuroticism score and BAI score (p = 0.028). Thus, an interaction term 
(neuroticism score*BAI score) was created and was included into the 
analysis for the final model.
Table 4 summarizes the results of MLR with the interaction term 
included. The three associative factors remained statistically significant 
after controlling for the interaction, with adjusted OR of 1.60 (95% CI 
1.27, 2.12), 1.44 (95% CI 1.08, 1.93), and 3.56 (95% CI 1.27, 10.01), 
respectively. The fitness of this final model was confirmed using 
Hosmer-Lemeshow test (p = 0.282), classification table (overall correct-
ly classified percentage = 83.4%), and area under the receiver operating 
characteristic (ROC 87.9%) curve test. In essence, the results show that 
after controlling for each other, neuroticism score, BAI score, and regu-
lar use of OTC analgesics were positively associated with the presence 
of CSP among patient on MMT.
The following predictor equation summarizes the above findings: 
Log (P/1-P) = -14.79C + 0.47(neuroticism score) + 0.37(BAI score) + 
1.27(regular OTC analgesic use) - 0.01(neuroticism score*BAI score)D. 
C is the regression coefficient of constant in the table of Variable in 
Equation from SPSS analysis for the final model, and D is the interac-
tion term included in the final model.
DISCUSSION
Current study established that CSP is a highly prevailing problem 
among patients on MMT in Alor Star, though the prevalence is lower 
compared to other studies1-3,29). Neuroticism score, BAI score, and regu-
lar use of OTC analgesics emerged as significant predictors of CSP 
among patient on MMT in the final model.
Neuroticism as an important associative factor with CSP among 
patients on MMT is consistent with previous studies30-32). Earlier studies 
postulated neuroticism as a vulnerability factor in chronic pain develop-
ment and was demonstrated by a later study that it predict the develop-
ment of chronic pain. Neuroticism has also been associated with internet 
addiction33) and depression34). Anxiety was found to be independently 
associated with CSP, which is consistent with other studies3,35). The pres-
ence of anxiety adversely affect the efficacy of cognitive behavioural 
therapy provided to the clients with chronic pain36).
Use of OTC analgesics as predictors suggested that when CSP was 
not adequately addressed, patients resorted to OTC analgesics to relieve 
their pain. OTC use as a way of self-medication was reported to be com-
mon, but the practice actually exposes the patient to adverse drug reac-
tions, which is avoidable37). Stone and colleagues reported that 95% of 
their surveyed subjects use OTC medication without doctor's prescrip-
tion, and analgesics are among the commonly reported. They further 
reported that among the subjects, as a result of their OTC use, exposure 
to the risk of drug-to-drug interaction is high. This implication is 
important for patients on MMT, especially those with chronic medical 
illnesses that required other medication, because drug-to-drug interac-
tion with methadone can be fatal38). Thus, steps must be taken to address 
the problem of OTC analgesic use among patients on MMT, one of 
which is proper assessment and treatment of CSP.
It is interesting to note that over 40% of the study subjects reported 
daily use of kratom product. Though its association with CSP was not 
statistically significant, its implication to our MMT patients cannot be 
ignored. Kratom has been increasingly reported locally, as well as glob-
ally, as an emerging illicit substance with high abuse potential17,39,40-42). 
Kratom is reported being used by local people to manage opioid with-
drawal symptoms, and current study result suggests that the same phe-
nomenon might be happening among local MMT patients. Due to its 
opioid-like chemical properties17), concomitant use of kratom while 
undergoing MMT is expected to affect methadone dose adjustment, 
symptom control, and may defeat the purpose of MMT in the first place. 
Thus, routine assessment of kratom use among patients on MMT is rec-
ommended. However, more robust studies are needed to clarify the 
Koh C. H. et al.18
impact and the severity of kratom use among this group of patients.
The authors recognized a few limitations in the study. Firstly, as the 
study was conducted in only one area of the state of Kedah (urban area, 
also the capital of the state), thus the result cannot be generalized to the 
whole state of Kedah, or Malaysia at large. The sample population was 
heterogeneous in the sense that the time of participation and the dura-
tion of MMT varied considerably among subjects. 
Based on the findings, several steps may improve the MMT pro-
gram. Firstly, routine assessment for CSP might be warranted for all 
MMT patients, as detection is the first step in addressing the problem. 
Then, if CSP is detected, other associated factors, including the ones 
observed to be significant in this study, should be sought for and man-
aged accordingly. For instance, if CSP is found to coexist with anxiety 
or depression in a particular patient, treatment of the anxiety or depres-
sion is paramount in the management of the CSP. Besides, even if the 
patient does not complain of CSP to the treating physician, the presence 
of associated factors like regular OTC analgesic use and persistent anxi-
ety or depression should alert the clinician to the possibility of distress-
ing pain symptoms. Pain with physical causes might require multidisci-
plinary comprehensive pain management, such as referral to a pain clin-
ic, while pain symptom with obvious psychological component is likely 
to require psychological intervention.
CONCLUSION
This study established a significant positive association between neu-
roticism and CSP among ex-opioid users on MMT. Similarly, indepen-
dent association with CSP were also observed for anxiety and regular use 
of OTC analgesics. Kratom use is common, and its negative impact on 
MMT programme cannot be underestimated. Future studies with more 
rigorous methodology, such as a prospective cohort study, should to be 
conducted in the future in order to further clarify the nature of the associ-
ation between neuroticism and CSP among ex-opioid users on MMT.
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